Cell Line Data Sheet for CHLA-10

Disease:	Primitive neuroectodermal tumor (PNET)
Phase of Therapy:	Post-Chemotherapy (Progressive Disease)
Treatment:	4 cycles of cisplatin, doxorubicin, cyclophosphamide, etoposide
Disease Stage:	
Gender:	Female
Age at diagnosis:	168 years
Race:	N/A
Age at sample collection:	N/A
Source of Culture:	Solid tumor (thoracic lymph node)
Primary Tumor Site:	Thorax
Date Established:	1987
EWS/FLI1 Status:	FLI1
p53 functionality:	Non-Functional
Karyotype:	
Modal No:	

R-IC50 (DIMSCAN*):
***see reference 3**

Vincristine (ng/ml)	Melphalan (µg/ml)	Etoposide (ng/ml)	Rapamycin (ng/ml)
0.39 ± 0.05	7.27 ± 1.20	0.12 ± 0.01	0.62 ± 0.08

Growth Conditions: Please see Protocols section at https://www.cccells.org/protocols.php
5% CO_2, 20% O_2, 37.0°C

Media Formulation: Please see Protocols section at https://www.cccells.org/protocols.php
Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)

Doubling Time: 32 hours

Growth Properties: Teardrop-shaped cells with processes, adherent, grow mostly in clumps

STR Profile: May be obtained at https://strdb.cccells.org/

Notes: The Childhood Cancer Repository has a matching direct-to-culture diagnosis cell line available from this same patient – CHLA-9

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.

Cell Line Data Sheet for CHLA-10

References:

1. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at Other Tumor Suppressor Loci in Neuroblastoma. Cancer Res. 61, 679-686, 2001. PubMed ID: 11212268
https://cancerres.aacrjournals.org/content/61/2/679.long

2. Batra S, Reynolds CP, Maurer BJ. Fenretinide cytotoxicity for Ewing's sarcoma (ES) and primitive neuroectodermal Tumor (PNET) cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Research 64: 5415-5424, 2004. PubMed ID: 15289350
https://cancerres.aacrjournals.org/content/64/15/5415.long

3. Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. Pediatr Blood Cancer 56: 239-249, 2011. PubMed ID: 20922763
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/

SEE NCI Pediatric Preclinical Testing Program references.

Cell Line Data Sheet for CHLA-10

Cell Line Name: **CHLA-10**

Low confluency (10x magnification)

High confluency (10x magnification)

Low confluency (20x magnification)

High confluency (20x magnification)